查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球生物製藥輔料製造市場 – 預測（2023-2035）
市場調查報告書
商品編碼
1403891

全球生物製藥輔料製造市場 – 預測（2023-2035）

Biopharmaceutical Excipient Manufacturing Market- Forecast (2023-2035)"
出版日期: | 出版商: IndustryARC | 英文 108 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

預計2035年，全球生物製藥輔料製造市場規模將達58.88億美元，2023年至2035年複合年增長率為4.9%。市場的主要驅動因素是久坐生活方式導致的慢性病增加、製藥公司對藥物開發的大量投資以及奈米技術等新技術的引入。例如，根據世界衛生組織（WHO）預測，到2050年左右，心血管疾病、癌症、糖尿病、呼吸系統疾病等慢性疾病將佔每年9,000萬人死亡的86%。然而，生物製藥產業目前面臨的主要挑戰是藥物副作用和環境友善製造流程的開發。

重點

  • 歐洲是全球最大的生物製藥輔料市場，2022年市佔率將達33%。由於區域產業的顯著成長，歐洲生物製藥輔料市場規模將從2022年的10.3億美元增加至2035年的17.6億美元，2023-2035年複合年增長率預計為4.1%。
  • 受美國經濟成長動能、強勁內需和印度強勁政府支出的推動，製藥公司對北美和亞太地區的經濟狀況持適度樂觀態度。亞太地區市場規模預計到2022年將達到7.5億美元，到2035年將達到17.1億美元，成長最快，複合年增長率為6.4%。
  • 依功能劃分，抗菌劑佔據主要市場份額，2022年將達24%。賦形劑透過提高藥物的溶解度和生物利用度以及控制 pH 值和張力，在生物製劑的開發中發揮重要作用。此外，生物製藥賦形劑還可作為填充劑、抗氧化劑和防腐劑。

驅動因素—生物製藥輔料製造市場

製藥公司對仿製藥市場的關注

市場參與者專注於創新生物製藥輔料的開發和商業化。例如，2021年4月，DFE Pharma宣布推出名為 "BioHale" 的新輔料產品線，以解決全球生物製藥業務的供應挑戰。此外，隨著對生物製藥輔料的需求增加，生產設施的地理範圍也在擴大。例如，2022 年 5 月，DFE Pharma 在印度開設了一家新工廠，為製藥公司提供快速配方服務，包括輔料，以採購正確的配方。

多功能輔料越來越受歡迎

業界對多功能生物製藥輔料的接受度也是市場擴張的驅動因素。多功能生物製藥輔料可有效率且有效地改善生物製藥製造流程。提高產品品質、增加產量和降低營運成本都是相關的好處。COVID-19 疫苗的成功很大程度上取決於其功效，而透過使用高效的藥物輸送系統已提高了功效。Ludiflash、F-MELT 和 Avicel CE-15 等多功能賦形劑專為 ODT 配方而設計。它們是客製化的，可在壓縮過程中提供完整性（在低壓下生產硬片），並在暴露於介質時快速崩解。它的處理方式使其分解時具有更奶油般的口感，並增加配方的整體適口性。在某些情況下（例如 Rudy Flash，其含有約 90% 甘露醇），賦形劑本身可以使產品變甜，從而減少配方中對甜味劑的需求。

該報告研究了全球生物製藥輔料製造市場，並提供了市場份額、驅動因素、細分市場、地區和主要參與者的分析。

目錄

第一章 前言

第 2 章執行摘要

第 3 章 簡介

  • 章節概述
  • 生物製藥輔料
  • 理想的輔料特性
  • 生物製藥輔料的分類
  • 生物製藥輔料的應用
  • 監管場景
  • 結論

第四章 市場狀況

  • 章節概述
  • 生物製藥輔料製造商：整體市場格局
    • 分析：按成立年份
    • 分析：按公司規模
    • 分析：依總部所在地
    • 分析：按地點劃分的生物製藥輔料生產設施
  • 分析：根據化學成分的賦形劑類型
    • 碳水化合物
    • 多元醇
    • 聚合物
    • 蛋白質/胺基酸
    • 鹽
    • 脂質
    • 其他
  • 分析：依功能依輔料類型分類
    • 表面活性劑
    • 穩定劑
    • 張力調節器
    • 填料
    • 緩衝劑
    • 溶解促進劑
    • 藥物輸送系統
    • 螯合劑
    • 抗菌劑
    • 抗氧化
    • 其他
  • 分析：根據化學結構的賦形劑類型
    • 有機的
    • 無機的
  • 分析：按管理規模
    • 臨床前
    • 臨床
    • 商業的
  • 分析：依配方類型
    • 液體或腸胃外
    • 堅硬的
  • 分析：依生物類型
    • 疫苗接種
    • 蛋白質/勝□
    • 細胞療法
    • 抗體
    • 血液製品
      • 分析：依全球監理合規性劃分
    • 美國藥典
    • 歐洲藥典
    • 日本藥典
    • 英國藥典
    • 中國藥典
    • 美國化學會等級
    • 印度藥典
    • F.C.C.
    • 台灣FDA

第五章企業競爭力分析

  • 章節概述
  • 假設和關鍵參數
  • 調查方法
  • 生物製藥輔料生產企業：企業競爭力分析
    • 企業競爭力分析：小企業
    • 企業競爭力分析：中型企業
    • 企業競爭力分析：大企業
    • 企業競爭力分析：超大型企業

第六章 公司簡介：生物製藥輔料生產企業

  • 章節概述
  • ABITEC
  • Avantor
  • BASF Pharma
  • Corden Pharma
  • DFE Pharma
  • Evonik
  • Kirsch Pharma
  • Merck KGaA
  • Pfanstiehl
  • Roquette
  • Spectrum Chemical Manufacturing
  • SPI Pharma

第 7 章 夥伴關係和聯盟

  • 章節概述
  • 合作模式
  • 生物製藥輔料製造市場：夥伴關係與聯盟
    • 分析：合作年
    • 分析：按合作夥伴類型
    • 分析：合作年份，依類型
    • 分析：按賦形劑類型
    • 分析：依藥物分子類型
    • 最活躍的公司：合作夥伴數量分析
    • 分析：按地區

第8章 近期擴張

  • 章節概述
  • 生物製藥輔料製造市場：近期擴張
    • 分析：按擴張年份
    • 分析：按擴充類型
    • 分析：依公司規模及總部地點
    • 分析：擴建設施選址
    • 分析：按賦形劑類型
    • 分析：依藥物分子類型
    • 最活躍的公司：近期擴張數據分析
    • 區域分析

第九章 產能分析

  • 章節概述
  • 主要假設及研究方法
  • 生物製藥輔料製造：全球活躍的生產能力
    • 分析：按公司規模
    • 分析：按管理規模
    • 分析：依製造設施的位置
  • 結論

第十章市場預測、機會分析

  • 章節概述
  • 預測方法及主要假設
  • 全球生物製藥輔料製造市場（2022-2035）
  • 生物製藥輔料製造市場：依生物製劑類型（2022 年和 2035 年）
  • 生物製藥輔料製造市場：依輔料類型劃分（2022年及2035年）
  • 生物製藥輔料製造市場：依公司規模劃分（2022/2035）
  • 生物製藥輔料製造市場：依業務規模劃分（2022/2035）
  • 生物製藥輔料製造市場：按地區（2022年及2035年）
    • 北美生物製藥輔料製造市場（2022-2035）
    • 歐洲生物製藥輔料製造市場（2022-2035）
    • 亞太生物製藥輔料製造市場（2022-2035）
    • 拉丁美洲生物製藥輔料製造市場（2022-2035）
    • 中東和北非生物製藥輔料製造市場（2022-2035）
    • 其他地區生物製藥輔料製造市場（2022-2035）

第11章結論

第十二章管理考慮

  • 章節概述
  • DFE Pharma

第十三章附錄一：資料表

第十四章 附錄2：公司與組織名單

簡介目錄
Product Code: HCR 1562

Biopharmaceutical Excipient Overview

The Biopharmaceutical Excipient Manufacturing Market size is forecast to reach USD 5,888.0 Million by 2035, after growing at a CAGR of 4.9% during 2023-2035. The major driving forces of this market are increasing incidences of chronic diseases owing to sedentary lifestyles; substantial investments by pharmaceutical companies in the development of medicines; and the implementation of new techniques such as nanotechnology. For instance, according to the World Health Organization, by around 2050, chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory illnesses will account for 86% of the 90 million deaths each year: a staggering 90% increase in absolute numbers, since 2019. However, the major challenges currently faced by the biopharmaceutical industry are the side effects of drugs; and developing environmental-friendly manufacturing processes.

Report Coverage

The report "Biopharmaceutical Excipient Manufacturing Market- Forecast (2023-2035)", by IndustryARC, covers an in-depth analysis of the following segments of the Biopharmaceutical Excipient Manufacturing market.

Distribution by Type of Excipient based on Chemical Composition: Carbohydrates, Polyols, Polymers, Proteins / amino acids, Salts, Lipids, Others,

Distribution by Type of Excipient based on Function: Surfactants, Stabilizers, Tonicity modifiers, Bulking agents, Buffering agents, Solubility enhancers, Drug delivery system, Chelators, Antimicrobials, Antioxidants, and Others;

Distribution by Type of Excipient based on Chemical Structure: Organic, Inorganic;

Distribution by Scale of Operation: Preclinical, Clinical, Commercial;

Distribution by Type of Biologic: Vaccines, Proteins / peptides, Cell therapies, Antibodies, Blood products;

Distribution by Company Size: Small, Mid-sized, Large, Very Large;

By Geography: North America, Europe, Asia-Pacific, Latin America, MENA, Rest of the World.

Key Takeaways

  • Europe is the world's largest market for biopharmaceutical excipients, with a leading market share of 33% in 2022. The European biopharmaceutical Excipients market is projected to grow with a CAGR of 4.1% from 2023 to 2035 with a market size of $1.03 billion in 2022 and $1.76 billion in 2035 owing to significant industrial growth in the region.
  • Pharmaceutical companies are slightly optimistic about economic conditions in North America and the Asia-Pacific due to positive momentum in the US, firm domestic demand, and strong government expenditure in India. Asia-Pacific is projected to grow with the fastest CAGR of 6.4% with a market size of $0.75 billion in 2022 and $1.71 billion in 2035.
  • Based on functions, Antimicrobials held the major market share of 24% in 2022. Excipients play a critical role in biologics development by enhancing the solubility and bioavailability, controlling the pH and tonicity of the APIs. Additionally, biopharmaceutical excipients act as bulking agents, antioxidants, or preservatives.

Distribution by Type of Excipient based on Chemical Composition - Segment Analysis

Proteins/Amino Acids dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. This is due to rising consumer spending capacity and greater individual awareness of preventative care and healthy lifestyles. They are used in health supplements to relieve muscle soreness and fatigue, as well as to minimize the risk of cardiovascular disease. Because of the popularity of veganism and vegetarianism, there is a growing demand for plant-based protein sources. Because plant-based proteins usually lack one or more key amino acids, amino acid supplements are used to ensure that people on plant-based diets get enough nutrients. They are also found in nutritional supplements, which are growing more popular as individuals strive to improve their health and well-being. Amino acid supplements are marketed for their possible benefits in terms of muscle building, athletic performance, and overall health.

Distribution by Type of Excipient based on Function - Segment Analysis

Antimicrobials dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. The antimicrobials industry is expected to increase quickly in recent years. The shift in growth trajectory is mostly due to firms resuming production after the COVID-19 epidemic, when demand increased considerably. With the exponential spread of coronavirus, the global antimicrobials market is predicted to grow significantly. Furthermore, the growing frequency of numerous bacterial infections would need the introduction of antimicrobials into the market. Antimicrobials are one of the most powerful types of chemotherapy and have been used to protect humans from infectious diseases. Antimicrobial agents destroy or delay microorganisms. Microorganisms include bacteria, viruses, protozoans, and fungi such as mold and mildew.

Distribution by Type of Excipient based on Chemical Structure - Segment Analysis

Organic dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. Growing pharmaceutical drug demand is predicted to drive the organic biopharmaceutical excipients market forward. Pharmaceutical drugs are chemical substances or compounds that are used to prevent, diagnose, treat, or relieve various diseases, medical conditions, or symptoms in humans. The increased need for pharmaceutical medications has increased the demand for organic pharmaceutical excipients, which provide acceptable and compatible constituents for organic drug formulations and aid in the physiological absorption of the drug. According to the European Federation of Pharmaceutical Industries and Associations, a Europe-based pharmaceutical industry association, global pharmaceuticals production increased by 4.6 percent in June 2022, from €286,697 million ($308,881 million) in 2020 to €300,000 ($323,214) in 2021.

Distribution by Scale of Operation - Segment Analysis

Clinical dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. The biopharmaceutical excipient market in clinical operation is driven by the increasing demand for biopharmaceutical drugs, especially in the treatment of chronic diseases such as cancer, diabetes, and autoimmune disorders. Biopharmaceutical drugs have unique formulation requirements, and excipients play a crucial role in meeting these requirements. The U.S. Food and Drug Administration (FDA) approved BASF Solutions' Soluplus® branded excipient in 2022 as part of its initiative to assess the acceptance and security of excipients for use in clinical trials without regard to a particular New Drug Application. Excipients, or inactive substances, like the trademarked Soluplus® excipient, are essential for facilitating the drug development process for active pharmaceutical compounds that are poorly soluble. In addition, the continuous advancements in biotechnology and drug delivery technologies have led to the development of novel excipients that can enhance the drug's bioavailability, stability, and therapeutic efficacy. This drives the demand for innovative excipients in clinical operations.

Distribution by Type of Biologic - Segment Analysis

Vaccines dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. The biopharmaceutical excipient market in vaccines is driven by the increasing demand for vaccines for preventive healthcare and disease control. In the creation of novel medications, biopharmaceuticals, and vaccinations to combat the coronavirus and other illnesses, excipients are essential. According to Excipient World, in 2020, a U.S.-based biotechnology firm has introduced Remdesivir an antiviral drug which emphasizes the crucial excipient that purified water had in the COVID-19 vaccine's development. With a population of over 330 million, the United States alone requires the production of at least 660 million doses of the COVID-19 vaccine. Millions of gallons of pharmaceutical-grade water are currently produced every day, most of which is used directly for vaccine development and testing. The rise in the production of vaccines is anticipated to drive the market growth.

Distribution by Company Size - Segment Analysis

Large dominated the Biopharmaceutical Excipient Manufacturing Market in 2022. When it comes to large company size, several factors play a role in the biopharmaceutical excipient market. Large pharmaceutical companies typically have a greater demand for excipients due to their extensive drug portfolios and production scale. Mid-sized companies in biopharmaceutical excipient manufacturers include Kerry Group, Avantor, Lubrizol Corp, BASF, Roquette Freres, FMC Corp, Croda International, Ashland Global Holdings, and ABITEC. These companies often engage in extensive research and development activities, leading to the formulation of various biopharmaceutical drugs that require different excipients.

Geography - Segment Analysis

Europe Biopharmaceutical Excipient Manufacturing Market generated a revenue of $1.03 Million in 2022 and is projected to reach a revenue of $1.76 Million by 2035 growing at a CAGR of 4.1% during 2023-2035. By promoting the best use of excipients in medications, the International Pharmaceutical Excipients Council (IPEC) Europe produces standards to improve patient safety. Since 1992, IPEC Europe has brought together manufacturers, distributors, and users of pharmaceutical excipients. Because of rising healthcare costs and an aging population, Europe's pharmaceutical industry is booming. This rise fuels the demand for pharmaceutical excipients, which are used to create new medications and improve current ones. Excipients in biopharmaceuticals play an important role in increasing medication stability, solubility, and bioavailability. Drug formulation processes and excipient functions are constantly improving, which drives market expansion. In recent years, the discovery of biological medications has resulted in significant changes in the pharmaceutical industry environment. Large corporations have shifted their focus away from small molecule medications and toward the discovery and production of complex biological chemicals produced by a range of species.

Drivers - Biopharmaceutical Excipient Manufacturing Market

The growing emphasis of pharmaceutical companies on the generic market

Key market participants are concentrating on the development and commercialization of innovative biopharmaceutical excipients. DFE Pharma, for example, released a new excipient product line called 'BioHale' in April 2021 to address global supply difficulties for biopharmaceutical businesses. Furthermore, as demand for biopharmaceutical excipients grows, manufacturing facilities are expanding geographically. For example, in May 2022, DFE Pharma launched a new facility in India to provide pharmaceutical players with fast-track formulation services, including excipients, to obtain the proper formulations.

Multifunctional excipients are becoming more popular

Industry acceptance of multi-functional biopharmaceutical excipients is also driving market expansion. They are efficient and effective in improving the biopharmaceutical manufacturing process. Better product quality, increased production, and lower operational costs are all associated benefits. The success of COVID-19 vaccines is mostly dependent on their effectiveness, which has been improved by the use of efficient drug delivery systems; this provides enormously lucrative potential for market entities. Multifunctional excipients such as Ludiflash, F-MELT, and Avicel CE-15 have been created specifically for ODT formulations. They are custom-made to provide binding during compression (to produce a hard tablet at a low compression pressure) and quick disintegration when exposed to a medium. They are handled in such a way that they disintegrate with a creamier mouthfeel, boosting the formulation's overall palatability. In some situations (such as Ludiflash, which contains around 90% mannitol), the excipient itself gives a sweet taste to the product, reducing the need for sweetener in the formulation.

Challenges - Biopharmaceutical Excipient Manufacturing Market

Manufacturing complexity

Some biopharmaceutical excipients, such as lipids, have sophisticated and capital-intensive manufacturing procedures. As a result, demand for pharmaceutical excipients for biologics has increased significantly. However, the accompanying manufacturing procedures for some biopharmaceutical excipients, such as lipids, are highly sophisticated, capital-intensive, and fraught with several problems. Excipient variability, excipient concentrations, capital-intensive manufacturing procedures, multiple difficulties, viscosity, analytical characterisation, and isotonic formulations can all contribute to the complexity of biopharmaceutical excipient manufacturing.

Regulatory approval

Because innovative excipients do not have a separate approval process, they can only be approved for a specific function in a medication dosage formulation. Pharmaceutical excipient manufacturing standards face many challenges: There is no special approval mechanism in place for novel excipients, Excipients do not have regulatory status in the United States, Excipients used in pharmaceutical preparations are not subject to any strict criteria.

Market Landscape

Technology launches, acquisitions, and R&D activities are key strategies adopted by players in the Biopharmaceutical Excipient Manufacturing market. In 2021, the Biopharmaceutical Excipient Manufacturing Market share has been consolidated by the top ten players accounting for 38.3% of the share. Major players in the Biopharmaceutical Excipient Manufacturing Market are Dupont, Evonik, BASF, FMC Crop., Ashland. Merck, Cargill, and others.

Developments:

On 2nd June 2023, Evonik introduced cutting-edge peptides for biopharmaceutical applications. Evonik cQrex® KC is a peptide that improves cell culture media performance and is utilized in the production of biological medicines. The biopharmaceutical industry's media formulators and cell culture process developers may now optimize cystine supply and boost cell culture productivity thanks to this novel peptide. The newest product in Evonik's arsenal of cQrex® cell culture chemicals, cQrex® KC, is intended to boost productivity and efficiency in cell culture procedures that generate viral vectors, cell treatments, vaccines, and monoclonal antibodies.

On 1st September 2022, the science and technology company Merck introduced Sodium Chloride Granulated EMPROVE EXPERT Ph Eur, BP, ChP, JP, USP, a multi-compendial excipient with broad applications in both pharma and biopharma. This expands the company's granulated product line.

On April 21, 2021, DFE Pharma, a German-based provider of biopharmaceutical excipient solutions, announced the launch of BioHale, a new product line designed to help biopharmaceutical firms with their global supply issues. The new line will supply manufacturers and drug developers with high-quality excipient technology and services to promote therapeutic formulation, as well as market purity and low endotoxin excipients for use in the formulation.

Table of Contents

1.PREFACE

  • 1.1. Scope of the Report
  • 1.2. Research Methodology
  • 1.3. Key Questions Answered
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Biopharmaceutical Excipients
  • 3.3. Properties of Ideal Excipients
  • 3.4. Classification of Biopharmaceutical Excipients
    • 3.4.1. Classification based on Route of Administration
    • 3.4.2. Classification of Excipients based on Structure
    • 3.4.3. Classification of Excipients based on Function
    • 3.4.4. Classification based on Ability to Interfere with Metabolization and Efflux Mechanisms
  • 3.5. Applications of Biopharmaceutical Excipients
  • 3.6. Regulatory Scenario
  • 3.7. Concluding Remarks

4. MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Biopharmaceutical Excipient Manufacturers: Overall Market Landscape
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Location of Biopharmaceutical Excipient Manufacturing Facilities
    • 4.2.5. Analysis by Type of Excipient based on Chemical Composition
  • Carbohydrates
  • Polyols
  • Polymers
  • Proteins / amino acids
  • Salts
  • Lipids
  • Others
    • 4.2.6. Analysis by Type of Excipient based on Function
  • Surfactants
  • Stabilizers
  • Tonicity modifiers
  • Bulking agents
  • Buffering agents
  • Solubility enhancers
  • Drug delivery system
  • Chelators
  • Antimicrobials
  • Antioxidants
  • Others
    • 4.2.7. Analysis by Type of Excipient based on Chemical Structure
  • Organic
  • Inorganic
    • 4.2.8. Analysis by Scale of Operation
  • Preclinical
  • Clinical
  • Commercial
    • 4.2.9. Analysis by Type of Formulation
  • Liquid or parenteral
  • Solid
    • 4.2.10. Analysis by Type of Biologic
  • Vaccines
  • Proteins / peptides
  • Cell therapies
  • Antibodies
  • Blood products
    • 4.2.11. Analysis by Global Regulatory Compliance
  • United States Pharmacopoeia / United States Pharmacopoeia-National Formulary
  • European Pharmacopoeia
  • Japanese Pharmacopoeia
  • British Pharmacopoeia
  • China Pharmacopoeia
  • American Chemical Society grade
  • Indian Pharmacopoeia
  • Food Chemical Codex
  • Taiwan FDA

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Assumptions and Key Parameters
  • 5.3. Methodology
  • 5.4. Biopharmaceutical Excipient Manufacturers: Company Competitiveness Analysis
    • 5.4.1. Company Competitiveness Analysis: Small Companies
    • 5.4.2. Company Competitiveness Analysis: Mid-Sized Companies
    • 5.4.3. Company Competitiveness Analysis: Large Companies
    • 5.4.4. Company Competitiveness Analysis: Very Large Companies

6. COMPANY PROFILES: BIOPHARMACEUTICAL EXCIPIENT MANUFACTURERS

  • 6.1. Chapter Overview
  • 6.2. ABITEC
    • 6.2.1. Company Overview
    • 6.2.2. Biopharmaceutical Excipient Offerings
    • 6.2.3. Manufacturing Facilities
    • 6.2.4. Recent Developments and Future Outlook
  • 6.3. Avantor
    • 6.3.1. Company Overview
    • 6.3.2. Financial Information
    • 6.3.3. Biopharmaceutical Excipient Offerings
    • 6.3.4. Manufacturing Facilities
    • 6.3.5. Recent Developments and Future Outlook
  • 6.4. BASF Pharma
    • 6.4.1. Company Overview
    • 6.4.2. Financial Information
    • 6.4.3. Biopharmaceutical Excipient Offerings
    • 6.4.4. Manufacturing Facilities
    • 6.4.5. Recent Developments and Future Outlook
  • 6.5. Corden Pharma
    • 6.5.1. Company Overview
    • 6.5.2. Biopharmaceutical Excipient Service Offerings
    • 6.5.3. Manufacturing Facilities
    • 6.5.4. Recent Developments and Future Outlook
  • 6.6. DFE Pharma
    • 6.6.1. Company Overview
    • 6.6.2. Biopharmaceutical Excipient Offerings
    • 6.6.3. Manufacturing Facilities
    • 6.6.4. Recent Developments and Future Outlook
  • 6.7. Evonik
    • 6.7.1. Company Overview
    • 6.7.2. Financial Information
    • 6.7.3. Biopharmaceutical Excipient Offerings
    • 6.7.4. Manufacturing Facilities
    • 6.7.5. Recent Developments and Future Outlook
  • 6.8. Kirsch Pharma
    • 6.8.1. Company Overview
    • 6.8.2. Biopharmaceutical Excipient Offerings
    • 6.8.3. Manufacturing Facilities
    • 6.8.4. Recent Developments and Future Outlook
  • 6.9. Merck KGaA
    • 6.9.1. Company Overview
    • 6.9.2. Financial Information
    • 6.9.3. Biopharmaceutical Excipient Offerings
    • 6.9.4. Manufacturing Facilities
    • 6.9.5. Recent Developments and Future Outlook
  • 6.10. Pfanstiehl
    • 6.10.1. Company Overview
    • 6.10.2. Biopharmaceutical Excipient Offerings
    • 6.10.3. Manufacturing Facilities
    • 6.10.4. Recent Developments and Future Outlook
  • 6.11. Roquette
    • 6.11.1. Company Overview
    • 6.11.2. Biopharmaceutical Excipient Offerings
    • 6.11.3. Manufacturing Facilities
    • 6.11.4. Recent Developments and Future Outlook
  • 6.12. Spectrum Chemical Manufacturing
    • 6.12.1. Company Overview
    • 6.12.2. Biopharmaceutical Excipient Offerings
    • 6.12.3. Manufacturing Facilities
    • 6.12.4. Recent Developments and Future Outlook
  • 6.13. SPI Pharma
    • 6.13.1. Company Overview
    • 6.13.2. Biopharmaceutical Excipient Offerings
    • 6.13.3. Manufacturing Facilities
    • 6.13.4. Recent Developments and Future Outlook

7. PARTNERSHIPS AND COLLABORATIONS

  • 7.1. Chapter Overview
  • 7.2. Partnership Models
  • 7.3. Biopharmaceutical Excipients Manufacturing Market: Partnerships and Collaborations
    • 7.3.1. Analysis by Year of Partnership
    • 7.3.2. Analysis by Type of Partnership
    • 7.3.3. Analysis by Year and Type of Partnership
    • 7.3.4. Analysis by Type of Excipient
    • 7.3.5. Analysis by Type of Drug Molecule
    • 7.3.5. Most Active Players: Analysis by Number of Partnerships
    • 7.3.6. Analysis by Geography
      • 7.3.6.1. Intercontinental and Intracontinental Deals
      • 7.3.6.2. International and Local Deals

8. RECENT EXPANSIONS

  • 8.1. Chapter Overview
  • 8.2. Biopharmaceutical Excipient Manufacturing Market: Recent Expansions
    • 8.2.1. Analysis by Year of Expansion
    • 8.2.2. Analysis by Type of Expansion
    • 8.2.3. Analysis by Company Size and Location of Headquarters
    • 8.2.4. Analysis by Location of Expanded Facility
    • 8.2.5. Analysis by Type of Excipient
    • 8.2.6. Analysis by Type of Drug Molecule
    • 8.2.7. Most Active Players: Analysis by Number of Recent Expansions
    • 8.2.8. Geographical Analysis
      • 8.2.8.1. Region-wise Distribution
      • 8.2.8.2. Country-wise Distribution

9. CAPACITY ANALYSIS

  • 9.1. Chapter Overview
  • 9.2. Key Assumptions and Methodology
  • 9.3. Biopharmaceutical Excipient Manufacturing: Installed Global Capacity
    • 9.3.1. Analysis by Company Size
    • 9.3.2. Analysis by Scale of Operation
    • 9.3.3. Analysis by Location of Manufacturing Facility
  • 9.4. Concluding Remarks

10. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 10.1. Chapter Overview
  • 10.2. Forecast Methodology and Key Assumptions
  • 10.3. Global Biopharmaceutical Excipient Manufacturing Market, 2022-2035
  • 10.4. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Biologic, 2022 and 2035
  • 10.5. Biopharmaceutical Excipient Manufacturing Market: Distribution by Type of Excipient, 2022 and 2035
  • 10.6. Biopharmaceutical Excipient Manufacturing Market: Distribution by Company Size, 2022 and 2035
  • 10.7. Biopharmaceutical Excipient Manufacturing Market: Distribution by Scale of Operation, 2022 and 2035
  • 10.8. Biopharmaceutical Excipient Manufacturing Market: Distribution by Region, 2022 and 2035
    • 10.8.1. Biopharmaceutical Excipient Manufacturing Market in North America, 2022-2035
    • 10.8.2. Biopharmaceutical Excipient Manufacturing Market in Europe, 2022-2035
    • 10.8.3. Biopharmaceutical Excipient Manufacturing Market in Asia Pacific, 2022-2035
    • 10.8.4. Biopharmaceutical Excipient Manufacturing Market in Latin America, 2022-2035
    • 10.8.5. Biopharmaceutical Excipient Manufacturing Market in MENA, 2022-2035
    • 10.8.6. Biopharmaceutical Excipient Manufacturing Market in Rest of the World, 2022-2035

11. CONCLUDING REMARKS

12. EXECUTIVE INSIGHTS

  • 12.1. Chapter Overview
  • 12.2. DFE Pharma
    • 12.2.1. Company Snapshot
    • 12.2.2. Interview Transcript: Jeannette M. Wetzel, Biopharma Sales Director

13. APPENDIX 1: TABULATED DATA

14. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS